IP Library › Granted Patent US 12,331,127
Granted Patent B2
US 12,331,127 · App. 18/461,760 · Granted Jun 17, 2025

Therapeutic uses of anti-GITR antibodies

Inventors: Robert Babb (River Edge, NJ); Drew Dudgeon (Montvale, NJ); Yu Huang (Ossining, NY); Rosalynn Molden (Shoreline, WA); William Olson (Yorktown Heights, NY); Matthew Sleeman (Yorktown Heights, NY); Dimitris Skokos (New York, NY); Bei Wang (Hastings-on-Hudson, NY)
Assignee: REGENERON PHARMACEUTICALS, INC.
C07K16/2878A61K39/3955A61P35/00A61K2039/505C07K2317/565C07K2317/732C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,331,127
App. No.
18/461,760
Granted
Jun 17, 2025
Kind
B2
Abstract

Provided herein are antibodies, and antigen-binding fragments thereof that specifically bind glucocorticoid-induced tumor necrosis factor receptor (GITR), compositions comprising the antibodies or antigen-binding fragments thereof, and methods of using the same, including, e.g., methods of treatment using the same.

Claims (61)

1. A method for treating cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an isolated antibody or antigen-binding fragment thereof that binds to glucocorticoid-induced tumor necrosis factor receptor (GITR) and a pharmaceutically acceptable carrier, wherein the antibody or antigen-binding fragment thereof comprises:

(i) three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:4, the HCDR2 comprises the amino acid sequence of SEQ ID NO:6, and the HCDR3 comprises the amino acid sequence selected from the group consisting of SEQ ID NO:24, SEQ ID NO:30, SEQ ID NO:36, and SEQ ID NO:42; and

(ii) three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), wherein the LCDR1 comprises the amino acid sequence of SEQ ID NO:12, the LCDR2 comprises the amino acid sequence of SEQ ID NO:14, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:16.

2. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 24, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

3. The method of claim 2 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO: 22.

4. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 30, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

5. The method of claim 4 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO: 28.

6. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 36, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

7. The method of claim 6 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO: 34.

8. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 42, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

9. The method of claim 8 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO: 40.

10. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises an LCVR having the amino acid sequence of SEQ ID NO: 10.

11. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 22, and an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

12. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 28, and an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

13. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 34, and an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

14. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 40, and an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

15. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is an antibody which comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 26.

16. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is an antibody which comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 32.

17. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is an antibody which comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 38.

18. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is an antibody which comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 44.

19. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is an antibody which comprises a heavy chain and a light chain, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 20.

20. The method of claim 1 , further comprising administering to the subject an agonistic antibody or antigen-binding fragment thereof that binds to a second T-cell activating receptor, wherein the T-cell activating receptor is CD28, OX40, CD137, CD27, or HVEM.

21. The method of claim 1 , further comprising administering to the subject a PD-1 inhibitor, CTLA-4 inhibitor, a TIM-3 inhibitor, a BTLA inhibitor, a LAG-3 inhibitor, or a VISTA antagonist.

22. The method of claim 21 , wherein the PD-1 inhibitor is cemiplimab.

23. The method of claim 1 , further comprising administering radiation therapy to the subject.

24. The method of claim 1 , further comprising administering one or more chemotherapeutic agents to the subject.

25. The method of claim 1 , wherein the cancer is selected from the group consisting of squamous cell skin cancer, cutaneous squamous cell carcinoma (CSCC), myeloma, lung cancer, including small cell lung cancer and non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (SCCHN), cervical cancer, including cervical squamous cell carcinoma (cervical SCC), renal cell carcinoma (RCC), adenocarcinoma, colorectal cancer (CRC), pancreatic carcinoma, head and neck cancer, prostate cancer, glioblastoma multiforme, malignant gliomas, osteosarcoma, gastric cancer, malignant mesothelioma, multiple myeloma, ovarian cancer, synovial sarcoma, thyroid cancer, breast cancer, including triple negative breast cancer, testicular cancer, esophageal cancer, uterine cancer, endometrial cancer, liver cancer, immune checkpoint blockade (ICB) naive cancer, and ICB experienced cancer.

26. The method of claim 2 , wherein the method further comprises administering to the subject a therapeutically effective amount of

cemiplimab.

27. A method for modulating anti-tumor immune response, the method comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to glucocorticoid-induced tumor necrosis factor receptor (GITR), wherein the antibody or antigen-binding fragment thereof comprises:

(i) three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:4, the HCDR2 comprises the amino acid sequence of SEQ ID NO:6, and the HCDR3 comprises the amino acid sequence selected from the group consisting of SEQ ID NO:24, SEQ ID NO:30, SEQ ID NO:36, and SEQ ID NO:42; and

(ii) three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), wherein the LCDR1 comprises the amino acid sequence of SEQ ID NO:12, the LCDR2 comprises the amino acid sequence of SEQ ID NO:14, and the LCDR3 comprises the amino acid sequence of SEQ ID NO:16.

28. The method of claim 27 , wherein the antibody or antigen-binding fragment thereof comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 24, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

29. The method of claim 28 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO: 22.

30. The method of claim 27 , wherein the antibody or antigen-binding fragment thereof comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 30, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

31. The method of claim 30 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO: 28.

32. The method of claim 27 , wherein the antibody or antigen-binding fragment thereof comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 36, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

33. The method of claim 32 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO: 34.

34. The method of claim 27 , wherein the antibody or antigen-binding fragment thereof comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 42, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.

35. The method of claim 34 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO: 40.

36. The method of claim 27 , wherein the antibody or antigen-binding fragment thereof comprises an LCVR having the amino acid sequence of SEQ ID NO: 10.

37. The method of claim 27 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 22, and an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

38. The method of claim 27 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 28, and an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

39. The method of claim 27 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 34, and an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

40. The method of claim 27 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 40, and an LCVR comprising the amino acid sequence of SEQ ID NO: 10.

41. The method of claim 27 , wherein the antibody or antigen-binding fragment thereof is an antibody which comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 26.

42. The method of claim 27 , wherein the antibody or antigen-binding fragment thereof is an antibody which comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 32.

43. The method of claim 27 , wherein the antibody or antigen-binding fragment thereof is an antibody which comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 38.

44. The method of claim 27 , wherein the antibody or antigen-binding fragment thereof is an antibody which comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 44.

45. The method of claim 27 , wherein the antibody or antigen-binding fragment thereof is an antibody which comprises a heavy chain and a light chain, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 20.

46. The method of claim 27 , further comprising administering to the subject an agonistic antibody or antigen-binding fragment thereof that binds to a second T-cell activating receptor, wherein the T-cell activating receptor is CD28, OX40, CD137, CD27, or HVEM.

47. The method of claim 27 , further comprising administering to the subject a PD-1 inhibitor, CLTA-4 inhibitor, a TIM-3 inhibitor, a BTLA inhibitor, a LAG-3 inhibitor, or a VISTA antagonist.

48. The method of claim 47 , wherein the PD-1 inhibitor is cemiplimab.

49. The method of claim 27 , further comprising administering radiation therapy to the subject.

50. The method of claim 27 , further comprising administering one or more chemotherapeutic agents to the subject.

51. The method of claim 27 , wherein the cancer is selected from the group consisting of squamous cell skin cancer, cutaneous squamous cell carcinoma (CSCC), myeloma, lung cancer, including small cell lung cancer and non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (SCCHN), cervical cancer, including cervical squamous cell carcinoma (cervical SCC), renal cell carcinoma (RCC), adenocarcinoma, colorectal cancer (CRC), pancreatic carcinoma, head and neck cancer, prostate cancer, glioblastoma multiforme, malignant gliomas, osteosarcoma, gastric cancer, malignant mesothelioma, multiple myeloma, ovarian cancer, synovial sarcoma, thyroid cancer, breast cancer, including triple negative breast cancer, testicular cancer, esophageal cancer, uterine cancer, endometrial cancer, liver cancer, immune checkpoint blockade (ICB) naive cancer, and ICB experienced cancer.

52. The method of claim 28 , wherein the method further comprises administering to the subject a therapeutically effective amount of cemiplimab.

53. A method for treating a cancer or modulating anti-tumor immune response in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of each of (i) an antibody or antigen-binding fragment thereof that specifically binds to GITR, and (ii) cemiplimab;

wherein the antibody or antigen-binding fragment thereof that specifically binds to GITR comprises an HCVR having the amino acid sequence of SEQ ID NO: 22 and an LCVR having the amino acid sequence of SEQ ID NO: 10.

54. The method of claim 53 , wherein the subject has a solid tumor.

55. The method of claim 53 , wherein the subject has head and neck squamous cell carcinoma.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2025
From: BABB, ROBERT; DUDGEON, DREW; HUANG, YU; MOLDEN, ROSALYNN; SLEEMAN, MATTHEW; SKOKOS, DIMITRIS; WANG, BEI; OLSON, WILLIAM
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 070469/0780 →
Continuity (3)
Division 17193586 · Mar 5, 2021
Provisional Application 62986494 · Mar 6, 2020
Related Publication 20240076396A1 · Mar 7, 2024
References Cited (108)
US 5500362A · Robinson et al. · 1996 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 6503184B1 · Ni et al. · 2003 [cited by applicant]
US 6689607B2 · Ni et al. · 2004 [cited by applicant]
US 7025962B1 · Gorman et al. · 2006 [cited by applicant]
US 7618632B2 · Collins et al. · 2009 [cited by applicant]
US 7812135B2 · Smith et al. · 2010 [cited by applicant]
US 8388967B2 · Smith et al. · 2013 [cited by applicant]
US 8709424B2 · Schebye et al. · 2014 [cited by applicant]
US 9028823B2 · Smith et al. · 2015 [cited by applicant]
US 9175308B2 · Shiku et al. · 2015 [cited by applicant]
US 9228016B2 · Wang et al. · 2016 [cited by applicant]
US 9309321B2 · Kwon · 2016 [cited by applicant]
US 9464139B2 · Beers et al. · 2016 [cited by applicant]
US 9493572B2 · Smith et al. · 2016 [cited by applicant]
US 9701751B2 · Schebye et al. · 2017 [cited by applicant]
US 9745379B2 · Wang et al. · 2017 [cited by applicant]
US 9987500B2 · Papadopoulos et al. · 2018 [cited by applicant]
US 10738126B2 · Delfino et al. · 2020 [cited by applicant]
US 11274342B2 · Zhang et al. · 2022 [cited by applicant]
US 11414494B2 · Delfino et al. · 2022 [cited by applicant]
US 11787867B2 · Babb et al. · 2023 [cited by applicant]
US 20060099171A1 · Tone et al. · 2006 [cited by applicant]
US 20070098719A1 · Smith et al. · 2007 [cited by applicant]
US 20070280945A1 · Stevens et al. · 2007 [cited by applicant]
US 20090136494A1 · Ponath et al. · 2009 [cited by applicant]
US 20100061984A1 · Greene et al. · 2010 [cited by applicant]
US 20110059109A1 · Smith et al. · 2011 [cited by applicant]
US 20110212086A1 · Shankara et al. · 2011 [cited by applicant]
US 20120189639A1 · Schebye et al. · 2012 [cited by applicant]
US 20130108641A1 · Baurin et al. · 2013 [cited by applicant]
US 20130183321A1 · Smith et al. · 2013 [cited by applicant]
US 20140072565A1 · Kwon · 2014 [cited by applicant]
US 20140072566A1 · Kwon · 2014 [cited by applicant]
US 20140348841A1 · Schebye et al. · 2014 [cited by applicant]
US 20150064204A1 · Beers et al. · 2015 [cited by applicant]
US 20150203579A1 · Papadopoulos et al. · 2015 [cited by applicant]
US 20150353637A1 · Wang et al. · 2015 [cited by applicant]
US 20150368349A1 · Seibert et al. · 2015 [cited by applicant]
US 20170355774A1 · Delfino et al. · 2017 [cited by applicant]
US 20210340267A1 · Babb et al. · 2021 [cited by applicant]
US 20230042324A1 · Delfino et al. · 2023 [cited by applicant]
EP 1462114 · 2004 [cited by applicant]
WO WO199806842A1 · 1998 [cited by applicant]
WO WO199925834 · 1999 [cited by applicant]
WO WO2004107618 · 2004 [cited by applicant]
WO WO2006105021A2 · 2006 [cited by applicant]
WO WO2011028683A1 · 2011 [cited by applicant]
WO WO2015026684A1 · 2015 [cited by applicant]
WO WO2015031667 · 2015 [cited by applicant]
WO WO2015184099A1 · 2015 [cited by applicant]
WO WO2015187835A2 · 2015 [cited by applicant]
WO WO2016054638 · 2016 [cited by applicant]
WO WO2016057846 · 2016 [cited by applicant]
WO WO2016070051A2 · 2016 [cited by applicant]
WO WO2017030823A2 · 2017 [cited by applicant]
WO WO2017214548A1 · 2017 [cited by applicant]
WO WO2018025178A1 · 2018 [cited by applicant]
Sanmamed et al., Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS, Sem. Oncol. 42(4):640-655, Aug. 2015. [cited by examiner]
Accession No. NP_004186.1 To: Protein [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; [2021]—Accession No. NP_004186.1, “Tumor Necrosis Factor Receptor Superf… [cited by applicant]
Altschul et al. (1990) “Basic Local Alignment Search Tool,” J. Mol. Biol., 215: 403-410. [cited by applicant]
Altschul et al. (1997) “Gapped Blast and PSI-Blast: A New Generation of Protein Database Search Programs,” Nucleic Acids Res., 25(17): 3389-3402. [cited by applicant]
Angal et al. (1993) “A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody,” Molecular Immunology, 30(1): 105-108. [cited by applicant]
Barbee, et al. (2016) “Novel Tetravalent Anti-GITR Antibody is a Potent Anti-tumor Agent In Vivo”, Annual Meeting in National Harbor, Maryland. Poster #175, Nov. 11, 2016, 1 page. [cited by applicant]
Clouthier et al. (2014) “Cell-specific and Context-dependent Effects of GITR in Cancer, Autoimmunity, and Infection,” Cytokine & Growth Factor Reviews, 25(2): 91-106. [cited by applicant]
Clynes et al. (1998) “Fc Receptors are Required in Passive and Active Immunity to Melanoma,” The National Academy of Sciences, 95: 652-656. [cited by applicant]
Dondelinger et al. (2018) “Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition,” Frontiers in Immunology, 9: 1-15. [cited by applicant]
Ehring (1999) “Hydrogen Exchange/Electrospray Ionization Mass Spectrometry Studies of Structural Features of Proteins and Protein/Protein Interactions,” Analytical Biochemistry, 267(2): 252-259. [cited by applicant]
Engen and Smith (2001) “The Basics of Ion Chromatography, Metrohm 792 Basic IC,” Anal. Chem., 73: 256A-265A. [cited by applicant]
Gershoni et al. (2007) “Epitope Mapping, The First Step in Developing Epitope-Based Vaccines,” BioDrugs, 21(3): 145-156. [cited by applicant]
Gonnet et al. (1992) “Exhaustive Matching of the Entire Protein Sequence Database,” Science 256: 1443-1445. [cited by applicant]
Harlow and Lane (2014) “Antibodies,” A Laboratory Manual, Second Edition, Cold Spring Harbor Press, Cold Spring Harbor, NY. [cited by applicant]
International Search Report and Written Opinion received in PCT/US2017/036818 on Nov. 6, 2017 (30 pages). [cited by applicant]
International Search Report and Written Opinion received in PCT/US2021/021109 on Jun. 21, 2021 (15 pages). [cited by applicant]
Junghans et al. (1990) “Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders,” Cancer Res., 50: 1495-1502. [cited by applicant]
Kanamaru et al. (2004) “Costimulation via Glucocorticoid-Induced TNF Receptor in Both Conventional and CD25+ Regulatory CD4+ T Cells,” J. Immunol., 172: 7306-7314 (10 pages) http://www.jimmunol.org/content/172/12/7306. [cited by applicant]
Kazane et al. (2012) “Synthesis of Bispecific Antibodies using Genetically Encoded Unnatural Amino Acids,” J. Am. Chem. Soc., [Epub: Dec. 4, 2012]. [cited by applicant]
Kazane et al. (2013) “Self-Assembled Antibody Multimers Through Peptide Nucleic Acid Conjugation,” J Am Chem Soc., 135(1): 340-346. [cited by applicant]
Klein et al. (2012) “Progress in Overcoming the Chain Association Issue in Bispecific Heterodimeric IgG Antibodies,” mAbs, 4(6): 1-11. [cited by applicant]
Knee et al. (2016) “Rationale for Anti-GITR Cancer Immunotherapy,” European Journal of Cancer, 67: 1-10. [cited by applicant]
Krausz et al. (2007) “GITR-GITRL System, a Novel Player in Shock and Inflammation,” The Scientific World Journal, 7: 533-566. [cited by applicant]
Kufer et al. (2004) “A Revival of Bispecific Antibodies,” Trends Biotechnol., 22(5): 238-244. [cited by applicant]
Langer (1990) “New Methods of Drug Delivery,” Science, 249: 1527-1533. [cited by applicant]
Langer and Wise (eds.) (1984) “Medical Applications of Controlled Release vol. II,” CRC Pres., Boca Raton, Florida, pp. 115-138. [cited by applicant]
Li et al. (2014) “Framework Selection Can Influence Pharmacokinetics of a Humanized Therapeutic Antibody Through Differences in Molecule Charge,” mABS, Landes Bioscience, US, 6(5): 1255-1264. [cited by applicant]
Lu et al. (2014) “Combined PD-1 Blockade and GITR Triggering Induce a Potent Antitumor Immunity in Murine Cancer Models and Synergizes with Chemotherapeutic Drugs,” Journal of Translational Medicine 12: 36 (11 pages). [cited by applicant]
Mordenti et al. (1991) “Interspecies Scaling of Clearance and Volume of Distribution Data for Five Therapeutic Proteins,” Pharmaceut. Res., 8: 1351-1359. [cited by applicant]
Nocentini et al. (2015) “Modulation of Tumour Immunity: A Patent Evaluation of WO 2015/026684A1,” Expert Opinion on Therapeutic Patents, 32 pages. [cited by applicant]
Padlan et al. (1995) “Identification of Specificity-Determining Residues in Antibodies,” FASEB J., 9: 133-139. [cited by applicant]
Pearson (1994) “Using the FASTA Program to Search Protein and DNA Sequence Database,” Methods Mol. Biol., 24: 307-331. [cited by applicant]
Pearson (2000) “Flexible Sequence Similarity Searching with the FASTA3 Program Package,” Methods in Molecular Biology, 132: 185-219. [cited by applicant]
Perez De La Lastra (1999) “Epitope Mapping 10 Monoclonal Antibodies Against the Pig Analogue of Human Membrane Cofactor Protein (MCP),” Immunology, 96: 663-670. [cited by applicant]
Powell et al. (1998) “Compendium of Excipients for Parenteral Formulations,” PDA, J Pharm Sci Technol, 52: 238-311. [cited by applicant]
Reddy et al. (2000) “Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4,” J. Immunol., 164: 1925-1933. [cited by applicant]
Reineke, (2004) “Antibody Epitope Mapping Using Arrays of Synthetic Peptides,” Methods Mol Biol., 248: 443-463. [cited by applicant]
Rudikoff et al. (1982) “Single Amino Acid Substitution Altering Antigen-binding Specificity,” Proc. Natl. Acad. Sci., 79: 1979-1983 (5 pages). [cited by applicant]
Schaer et al. (2012) “Modulation of GITR for Cancer Immunotherapy,” Curr. Opin. Immunol., 24: 217-224. [cited by applicant]
Sefton (1987) “Implantable Pumps,” CRC Crit. Ref. Biomed. Eng., 14(3): 201-240. [cited by applicant]
Shevach and Stephens (2006) “The GITR-GITRL interaction: Co-stimulation or Contrasuppression of Regulatory Activity?” Nat. Rev. Immunol., 6: 613-618. [cited by applicant]
Shields et al. (2002) “Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcyRIII and Antibody-dependent Cellular Toxicity,” JBC, 277(30): 26733-26740. [cited by applicant]
Shimizu et al. (2002) “Stimulation of CD25(+)CD4(+) Regulatory T Cells Through GITR Breaks Immunological Self-Tolerance,” Nature Immunology, 3(2): 135-142. [cited by applicant]
Taylor et al. (1992) “A Transgenic Mouse that Expresses a Diversity of Human Sequence Heavy and Light Chain Immunoglobulins,” Nucl. Acids Res., 20(23): 6287-6295. [cited by applicant]
Tomer et al. (2000) “Characterization of a Discontinuous Epitope of the Human Immunodeficiency Virus (HIV) Core Protein p24 by Epitope Excision and Differential Chemical Modification Followed by Mass Spectrometric Pepti… [cited by applicant]
Tutt et al. (1991)“Trispecific F(ab')3 Derivatives That Use Cooperative Signaling via the TCR/CD3 Complex and CD2 to Activate and Redirect Resting Cytotoxic T Cells,” J. Immunol., 147: 60-69. [cited by applicant]
Vajdos et al. (2002) “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis,” J Mol Biol., 320: 415-428. [cited by applicant]
Wu et al. (1987) “Receptor-Mediated in Vitro Gene Transformation by a Soluble DNA Carrier System,” J. Biol. Chem., 262: 4429-4432. [cited by applicant]
Yang et al. (2015) “TCRklass: A New K-String-Based Algorithm Characterization for Human and Mouse TCR Repertoire,” The Journal of Immunology, 194: 446-454. [cited by applicant]
Zhao et al. (2015) “Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib,” PLoS ONE, pp. 1-12. [cited by applicant]